Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Abstract

The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergistically enhanced etoposide-induced antiproliferative effects in lymphohematopoietic cell lines and acute myelogenous leukemia isolates. We subsequently conducted a phase 1 trial of tipifarnib plus etoposide in adults over 70 years of age who were not candidates for conventional therapy. A total of 84 patients (median age, 77 years) received 224 cycles of oral tipifarnib (300-600 mg twice daily for 14 or 21 days) plus oral etoposide (100-200 mg daily on days 1-3 and 8-10). Dose-limiting toxicities occurred with 21-day tipifarnib. Complete remissions were achieved in 16 of 54 (30%) receiving 14-day tipifarnib versus 5 of 30 (17%) receiving 21-day tipifarnib. Complete remissions occurred in 50% of two 14-day tipifarnib cohorts: 3A (tipifarnib 600, etoposide 100) and 8A (tipifarnib 400, etoposide 200). In vivo, tipifarnib plus etoposide decreased ribosomal S6 protein phosphorylation and increased histone H2AX phosphorylation and apoptosis. Tipifarnib plus etoposide is a promising orally bioavailable regimen that warrants further evaluation in elderly adults who are not candidates for conventional induction chemotherapy. These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853.

DOI: 10.1182/blood-2008-08-172726

14 Figures and Tables

Statistics

0200400200920102011201220132014201520162017
Citations per Year

990 Citations

Semantic Scholar estimates that this publication has 990 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Karp2009ActiveOR, title={Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.}, author={Judith E. Karp and Karen S. Flatten and Eric J. Feldman and Jacqueline M. Greer and David A. Loegering and Rebecca M. Ricklis and Lawrence Morris and Ellen Kelly Ritchie and Bruce D. Smith and Valerie Ironside and Timothy Talbott and Gail J. Roboz and Son B. Le and Xue Wei Meng and Paula A. Schneider and Nga T. Dai and Araba A. Adjei and Steven D Gore and Mark J. Levis and J. J. Wright and Elizabeth Garrett-Mayer and Scott H. Kaufmann}, journal={Blood}, year={2009}, volume={113 20}, pages={4841-52} }